Abstract:BACKGROUND:Randomized controlled trials are considered the gold standard for evaluating experimental treatments but often require large sample sizes. Single-arm trials require smaller sample sizes but are subject to bias when using historical control data for comparative inferences. This article presents a Bayesian adaptive synthetic-control design that exploits historical control data to create a hybrid of a single-arm trial and a randomized controlled trial.METHODS:The Bayesian adaptive synthetic control design has two stages. In stage 1, a prespecified number of patients are enrolled in a single arm given the experimental treatment. Based on the stage 1 data, applying propensity score matching and Bayesian posterior prediction methods, the usefulness of the historical control data for identifying a pseudo sample of matched synthetic-control patients for making comparative inferences is evaluated. If a sufficient number of synthetic controls can be identified, the single-arm trial is continued. If not, the trial is switched to a randomized controlled trial. The performance of The Bayesian adaptive synthetic control design is evaluated by computer simulation.RESULTS:The Bayesian adaptive synthetic control design achieves power and unbiasedness similar to a randomized controlled trial but on average requires a much smaller sample size, provided that the historical control data patients are sufficiently comparable to the trial patients so that a good number of matched controls can be identified in the historical control data. Compared to a single-arm trial, The Bayesian adaptive synthetic control design yields much higher power and much smaller bias.CONCLUSION:The Bayesian adaptive synthetic-control design provides a useful tool for exploiting historical control data to improve the efficiency of single-arm phase II clinical trials, while addressing the problem of bias when comparing trial results to historical control data. The proposed design achieves power similar to a randomized controlled trial but may require a substantially smaller sample size.

Constrained Markov decision processes for response-adaptive procedures in clinical trials with binary outcomes

A Markov decision process for response-adaptive randomization in clinical trials

BOP2: Bayesian Optimal Design for Phase II Clinical Trials with Simple and Complex Endpoints.

Bayesian Optimal Phase II Designs with Dual‐criterion Decision Making

Nonparametric Response-Adaptive Randomization for Continuous Responses

Adaptive Randomization for Clinical Trials with Delayed Response

BASIC: A Bayesian Adaptive Synthetic-Control Design for Phase II Clinical Trials.

Optimal Bayesian predictive probability for delayed response in single-arm clinical trials with binary efficacy outcome

A Bayesian Platform Trial Design to Simultaneously Evaluate Multiple Drugs in Multiple Indications with Mixed Endpoints.

A safe exploration approach to constrained Markov decision processes

A response‐adaptive randomization procedure for multi‐armed clinical trials with normally distributed outcomes

Bayesian Optimal Phase II Design for Randomized Clinical Trials

Decision-making with multiple correlated binary outcomes in clinical trials

Adaptive dose-response studies to establish proof-of-concept in learning-phase clinical trials

Personalized Dynamic Treatment Regimes in Continuous Time: A Bayesian Approach for Optimizing Clinical Decisions with Timing

A Bayesian Phase II Proof-of-concept Design for Clinical Trials with Longitudinal Endpoints.

A Bayesian Response-Adaptive Covariate-Balanced Randomization Design with Application to A Leukemia Clinical Trial

Experimenting on Markov Decision Processes with Local Treatments

Multi-armed Bandit Models for the Optimal Design of Clinical Trials: Benefits and Challenges

Making SMART decisions in prophylaxis and treatment studies

Constrained Risk-Averse Markov Decision Processes